Literature DB >> 21489588

Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance.

Lietta Nicolaides1, Clare Davy, Kenneth Raj, Christian Kranjec, Lawrence Banks, John Doorbar.   

Abstract

The E6 protein from high-risk human papillomaviruses appears necessary for persistence of viral episomes in cells but the underlying mechanism is unclear. E6 has many activities, including its ability to bind and degrade PDZ domain-containing proteins, such as hScrib. However little is known about the role of these interactions for E6 function and the viral life cycle. We now show that the levels of expression of wild-type E6 are increased in the presence of hScrib whilst a mutant E6 protein lacking the PDZ-binding motif is found at lower levels as it is turned over more rapidly by the proteasome. This correlates with an inability of genomes containing this mutation to be maintained as episomes. These results show that E6 association with certain PDZ domain-containing proteins can stabilize the levels of E6 expression and provides one explanation as to how the PDZ-binding capacity of E6 might contribute to genome episomal maintenance. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21489588     DOI: 10.1016/j.virol.2011.03.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance.

Authors:  Nicole Brimer; Scott B Vande Pol
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.

Authors:  Nathaniel Edward Bennett Saidu; Vedrana Filić; Miranda Thomas; Vanessa Sarabia-Vega; Anamaria Đukić; Frane Miljković; Lawrence Banks; Vjekoslav Tomaić
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

3.  PDZRN3/LNX3 is a novel target of human papillomavirus type 16 (HPV-16) and HPV-18 E6.

Authors:  Miranda Thomas; Lawrence Banks
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

4.  Cancer-causing human papillomavirus E6 proteins display major differences in the phospho-regulation of their PDZ interactions.

Authors:  Siaw Shi Boon; Vjekoslav Tomaić; Miranda Thomas; Sally Roberts; Lawrence Banks
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

5.  High-risk human papillomavirus E6 oncoproteins interact with 14-3-3ζ in a PDZ binding motif-dependent manner.

Authors:  Siaw Shi Boon; Lawrence Banks
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 6.  Human tumour viruses and the deregulation of cell polarity in cancer.

Authors:  Lawrence Banks; David Pim; Miranda Thomas
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

7.  The invasive capacity of HPV transformed cells requires the hDlg-dependent enhancement of SGEF/RhoG activity.

Authors:  Vanitha Krishna Subbaiah; Paola Massimi; Siaw Shi Boon; Michael P Myers; Lisa Sharek; Rafael Garcia-Mata; Lawrence Banks
Journal:  PLoS Pathog       Date:  2012-02-23       Impact factor: 6.823

Review 8.  The Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy.

Authors:  Ketaki Ganti; Justyna Broniarczyk; Wiem Manoubi; Paola Massimi; Suruchi Mittal; David Pim; Anita Szalmas; Jayashree Thatte; Miranda Thomas; Vjekoslav Tomaić; Lawrence Banks
Journal:  Viruses       Date:  2015-07-02       Impact factor: 5.048

9.  Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain.

Authors:  André Mischo; Oliver Ohlenschläger; Peter Hortschansky; Ramadurai Ramachandran; Matthias Görlach
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

10.  PDZ domains and viral infection: versatile potentials of HPV-PDZ interactions in relation to malignancy.

Authors:  Kazunori Nagasaka; Kei Kawana; Yutaka Osuga; Tomoyuki Fujii
Journal:  Biomed Res Int       Date:  2013-09-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.